UPDATED Mar 25, 2024
Annually loss-making mid-caps and large-caps with sound financial health.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
---|---|---|---|---|---|---|---|---|---|---|
PTVE | US$13.93 | 6.7% | 78.6% | US$2.5b | US$16.43 | PB1.8x | E74.3% | 2.9% | ||
NEM | US$33.92 | -1.5% | -29.6% | US$38.9b | US$45.08 | PS3.3x | E46.3% | 2.9% | ||
AU | US$21.34 | 0.8% | n/a | US$8.8b | US$21.75 | PS1.9x | E60.2% | 0.9% | ||
DNA | US$1.09 | 0% | -11.4% | US$2.1b | US$1.97 | PS8.7x | E22.4% | n/a |